Litigation Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
| Docket | See Plans and Pricing | Date Filed | 2018-03-15 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
| Jury Demand | None | Referred To | Leda Dunn Wettre |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 10,195,214; 8,921,348; 9,829,495; 9,943,526 | ||
| Attorneys | CHRISTINE INTROMASSO GANNON | ||
| Firms | Saul Ewing Arnstein & Lehr LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patents cited in this case is See Plans and Pricing .
Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-04-20 | Summary Judgment of Infringement of U.S. Patent No. 10,195,214. Motion set for 6/21/2021 before Judge Susan… 15 March 2018 2:18-cv-03632 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | ||
| 2018-07-06 | 15 | Amended Complaint | of United States Patent Nos. 8,921,348 (“’348 patent”), 9,829,495 (“’495 patent”), and 9,943,526 … States Patent (10) Patent No.: US 8,921,348 B2 … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 44. … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 52. … US 8,921,348 B2 1 | External link to document |
| 2020-06-23 | 152 | Opinion | The ’348 Patent and ’495 Patent, along with U.S. Patent No. 10,195,214 (“the ’214 Patent”), are collectively… regarding patent claims in Plaintiff’s U.S. Patent Nos. 8,921,348 (“the ʼ348 Patent”) and 9,829,495…regarding their request for patent claim construction pursuant to Local Patent Rule 4.5(a). This Court has…treatment by mifepristone.” (’348 Patent at Abstract.) 7 According to the patent, “administration of the same…produce excess cortisol. (’495 Patent at 1:23–24, 2:24– 29.) The ’495 Patent discloses a method to differentially | External link to document |
| 2021-04-09 | 197 | Certificate of Service | Summary Judgment of Infringement of U.S. Patent No. 10,195,214 by CORCEPT THERAPEUTICS, INC.. (Attachments… 15 March 2018 2:18-cv-03632 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-04-09 | 198 | Memorandum in Support of Motion | Summary Judgment of Infringement of U.S. Patent No. 10,195,214 (Attachments: # 1 Declaration of N. LoCastro… 15 March 2018 2:18-cv-03632 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-04-09 | 199 | Statement of Material Fact in Support of Motion | Summary Judgment of Infringement of U.S. Patent No. 10,195,214 (BATON, WILLIAM)NOTICE TO COUNSEL: Counsel… 15 March 2018 2:18-cv-03632 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
